Verteporfin (CL 318952)

For research use only. Not for use in humans.

製品コードS1786 別名：Visudyne

CAS No. 129497-78-5

Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 50500
10mg	JPY 55100
50mg	JPY 163000

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(101)

製品安全説明書

VDA阻害剤の選択性比較

生物活性

製品説明

ターゲット

VDA ^[1]
(Endothelial cells)

YAP/TEAD interaction ^[3]
()

体外試験

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. ^[1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. ^[2]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HL-60	NIfSd2hHfW6ldHnvckBie3OjeR?=	MXn+NVAxKG6pL33M		NUjSZ\|l6TE2VTx?=	Mn73bY5kemWjc3XzJGRPSSCocnHncYVvfGG2aX;uJIxmfmWucx?=	M2m4OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNkC3O\|ExLz5zME[wO\|cyODxxYU6=
HL-60	M2jBfoN6fG:2b4jpZ4l1gSCjc4PhfS=>	MnXJglExOCCwZz;tUC=>		M3;yOWROW09?	MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODZyN{exNEc,OTB4MEe3NVA9N2F-
Jurkat	NX[2OXJISXCxcITvd4l{KGG\|c3H5	MnXsglI5OCCwTR?=		NF[0THpFVVOR	MnqzbY5lfWOnczDhJGJkdC1{LXTldIVv\GWwdDDhdI9xfG:\|aYO=	NWnLXpNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGyOFU1OTVpPkGxNlQ2PDF3PD;hQi=>
RIF-1	M1;XPWZ2dmO2aX;uJIF{e2G7	MlfoNUDPxGdxbXy=		NV7qWZdZTE2VTx?=	M{LOW4Rm[3KnYYPld{BwgHmpZX6gZ49ve3WvcITpc44>	NVLYTXpCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2NVU4OThpPkGyOlE2PzF6PD;hQi=>
RIF-1	MlezZ5l1d3SxeHnjbZR6KGG\|c3H5	M1m4d\|Eh\|rypL33s		MWTEUXNQ	M17mZ4Rm[3KnYYPlJJRwKDJyINMxJFUmKGOnbHygd5Vzfmm4YXy=	NYfaO\|hHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2NVU4OThpPkGyOlE2PzF6PD;hQi=>
SVEC4-10	M370fmZ2dmO2aX;uJIF{e2G7	NYTGZpB[OjByIH7nM41t		NX\lboFyTE2VTx?=	NILIPJVqdmS3Y3XzJI1q[3KxdIXieYxmKGSncH;sfY1memm8YYTpc44>	NF\JOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS2O\|ExPid-MU[0OlcyODZ:L3G+
SVEC4-10	NVjreZVnTnWwY4Tpc44h[XO\|YYm=	M{L4RVIxOCCwZz;tcC=>		M2[xPWROW09?	NHXSdIZqdmS3Y3XzJJN1emW\|czDhZ5RqdiCoaXLldkBnd3KvYYTpc44>	M2OxZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NE[3NVA3Lz5zNkS2O\|ExPjxxYU6=
ARPE-19	NWPVc3N7[3m2b4TvfIlkcXS7IHHzd4F6	NYDhcHd2hjBwMTFOwIcwdWx?		MVPEUXNQ	MoXQd4hwf3NiYTDkc5NmNWSncHXu[IVvfCC2b4jpZ4l1gQ>?	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7OEe5NFUoRjF4OUi3PVA2RC:jPh?=
ARPE-19	M4P4VmZ2dmO2aX;uJIF{e2G7	NVfWeJhKOC5yMTFOwIcwdWx?		MWHEUXNQ	NH\wV5lqdmO{ZXHz[ZMhXkWJRjDhcoQhemWmdXPld{BRTUSIIHX4dJJme3Orb36=	MmHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7OEe5NFUoRjF4OUi3PVA2RC:jPh?=
Y-79	MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIHr[2t,OSEQvHevcYw>		NFP3eJFFVVOR	MWHk[YNz\WG\|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w	M3:xdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUe5O\|Y1Lz5zOEW3PVc3PDxxYU6=
WERI-Rb1	NYHn[ZR7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1jLWp4yKM7:Zz;tcC=>		M4fOXGROW09?	NHj3dXll\WO{ZXHz[ZMhemW2aX7vZoxie3SxbXGgZ4VtdCCycn;sbYZmemG2aX;u	MnTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3OlQoRjF6NUe5O\|Y1RC:jPh?=
RB247C3	Mm\ES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUnod\|ZFhjFizsznM41t		MkPGSG1UVw>?	MUPk[YNz\WG\|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5OUe2OEc,OTh3N{m3OlQ9N2F-
RB355	NF\GSWFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MX3+NUDPxGdxbXy=		MVnEUXNQ	MYPk[YNz\WG\|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w	NW\sSXN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|k4PjRpPkG4OVc6PzZ2PD;hQi=>
RB383	MonpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXTTUXAzhjFizsznM41t		MVXEUXNQ	MnX0[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?=	NVf0fodtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|k4PjRpPkG4OVc6PzZ2PD;hQi=>
hFibro	M4DQ[IN6fG:2b4jpZ4l1gSCjc4PhfS=>	MoTONE42KML3Zz;tcC=>		NUi4Z3o5TE2VTx?=	NWLibHNj\GWlcnXhd4V{KH[rYXLpcIl1gSCkeTC4Okw2LQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2MUGxOEc,OjN2NEGxNVQ9N2F-
pTMC	M4S0T4N6fG:2b4jpZ4l1gSCjc4PhfS=>	M2\OUlAvPSEEtXevcYw>		M1j0[WROW09?	Mnn0[IVkemWjc3XzJJZq[WKrbHn0fUBjgSB7Mj65KS=>	Mn:0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEGxNVQoRjJ\|NESxNVE1RC:jPh?=
hTMC	MlrJZ5l1d3SxeHnjbZR6KGG\|c3H5	M{\QNVAvPSEEtXevcYw>		NW\4[4E3TE2VTx?=	MmXw[IVkemWjc3XzJJZq[WKrbHn0fUBjgSB6OD65KS=>	Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEGxNVQoRjJ\|NESxNVE1RC:jPh?=
ARPE-19	NFTDS5lkgXSxdH;4bYNqfHliYYPzZZk>	NGftU3AxNjViwsXnM41t		MmnzSG1UVw>?	Mlvt[IVkemWjc3XzJJZq[WKrbHn0fUBjgSB3NT61KS=>	M13kNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NESxNVE1Lz5{M{S0NVEyPDxxYU6=
Panc-1	NFvwXYtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXHDO5lnOTBizszN		MnnkSG1UVw>?	M4DmWolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=>	MmHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmwOlkoRjJ2ME[5NFY6RC:jPh?=
MIA PaCa-2	M2\1d2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{n1dVExKM7:TR?=		NVz6Wmt1TE2VTx?=	NX\ETpZtcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v	NWLEcJJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlkxPjlpPkK0NFY6ODZ7PD;hQi=>
BxPC-3	MoT5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXHYRZFxOTBizszN		NIDzemVFVVOR	NIjNO2pqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgQ>?	NFr3bJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
SU86.86	M1zhSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1jLdFExKM7:TR?=		NUH0N4I3TE2VTx?=	MWrpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfS=>	M17lVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[5NFY6Lz5{NEC2PVA3QTxxYU6=
MCF-7	M{nzUGF2fG:yaHHnfUBie3OjeR?=	M3qzbVExKM7:TR?=		MoTESG1UVw>?	NF75SpdqdmirYnn0d{Bo\W2laYThZolv\S2rbnT1Z4VlKGG3dH;wbIFogQ>?	NFe1NpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
WERI	NETqPYRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFS5[Ih,OTBizsznM41t		Mk\ZSG1UVw>?	NG\KRXRqdmirYnn0d{Boem:5dHigc4YhemW2aX7vZoxie3SxbXGgZ4VtdHN?	NX[wOnBXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|cyPDJpPkK0PFM4OTR{PD;hQi=>
WERI	M13mWGZ2dmO2aX;uJIF{e2G7	NWLoSmpjhjFyIN88[{9udA>?		MXzEUXNQ	NHPrfohjdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdg>?	NWC2eWhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|cyPDJpPkK0PFM4OTR{PD;hQi=>
Y-79	MWLGeY5kfGmxbjDhd5NigQ>?	MV3+NVAh\|rypL33s		NG\MXZVFVVOR	M4T1SoJtd2OtczDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9v	NY\obpk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|cyPDJpPkK0PFM4OTR{PD;hQi=>
Y-79	NH;mNGJHfW6ldHnvckBie3OjeR?=	M3\tTZ4yOCEQvHevcYw>		M{XHT2ROW09?	NGDqTXNi\m[nY4TzJHlCWC2WRVHEJJBzd3SxLX;uZ49o\W6nIIDheIh4[Xl?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|N{G0Nkc,OjR6M{exOFI9N2F-
Y-79	MWjGeY5kfGmxbjDhd5NigQ>?	MVH+NVAh\|rypL33s		NGjB[2NFVVOR	Mlrp[I94di2{ZXf1cIF1\XNicHz1dolxd3SnbnP5JI1iemuncjDPR3QuPA>?	MorqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{exOFIoRjJ2OEO3NVQzRC:jPh?=
Phototoxicity assay	M4Tn[2IyPkZzMB?=		M3r3WFI1KGi{cx?=		M2nIeGlEPTBiPTCxMlA4KM7:TR?=	NWTxTWJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|Y{QDlpPkK3NVM3Ozh7PD;hQi=>
Phototoxicity assay	NHnSNW5DOT[IMUC=		M32wRlI1KGi{cx?=		NF30RVBKSzVyIE2gNU4zKM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|NkO4PUc,OjdzM{[zPFk9N2F-
Phototoxicity assay	NHvWbWNCOzd3		MUGyOEBpenN?		NELl[oRKSzVyIE2gNk4xPiEQvF2=	MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N\|g6RC:jPh?=
Dark toxicity assay	NXPoc4R7SjF4RkGw		NF\IUXo1QCCqcoO=		NGfnVJJKSzVyIE2gNlQvQTJizszN	M1zscVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N\|g6Lz5{N{GzOlM5QTxxYU6=
Dark toxicity assay	Ml;RRlE3TjFy		M1q3VlQ5KGi{cx?=		NYXrRmpyUUN3MDC9JFI2NjB\|IN88US=>	M1KwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N\|g6Lz5{N{GzOlM5QTxxYU6=
Dark toxicity assay	M3PmbWE{PzV?		NH;qOXo1QCCqcoO=		MoXRTWM2OCB;IEO2MlM{KM7:TR?=	NFnHZno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzOlM5QSd-MkexN\|Y{QDl:L3G+
qHTS assay	NEHZOVBVSzN{				NIn3O5FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NXvGOXFOXS1{IF;T				MlLGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	NUO5UIl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NUjQfVNxSTZ5Mx?=				NHfUXG5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NF3abFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NE\1fIFFSU:\				MnfpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NV3sXJFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MlK1V4Fwey1{				NXvOOJZjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NFru[ZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M1nyeGJVNTN5				Moq1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	M{jBO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NW\kVVZKWkR?				Mn7ydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NVLTcVl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NFG2UpZUUy2QLWPI				MmXJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MlT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NFP5dYNDXC1zMh?=				MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NFH6b2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NHfpcWNOTyB4MzCoOk1VTyCUKR?=				MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	Mln0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MV3PTHMuPTB?				MlPNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	Mn7WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NVvF[lVmWmh2MR?=				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NH7kRVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	MVXTTk1ISk1{				M3rjR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MmnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NG\GOJZUUy2QLV3D				NYXwbWJpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NFHqUHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M3zhe2xCVi13				NH3Y[4hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	NGLpeoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Antitumor assay	NHPKbFNDOT[IMUC=	M4HDSVIhdWdxa3e=	MYOyJIhzew>?		MXLBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDCNVZHOTBiY3XscJMhcW2ybHHueIVlKGmwIFO1O2JNNzZibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMjDt[{9s\yxiaY[gZYRucW6rc4TldoVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDpdpJi\GmjdHnvckB4cXSqIHzhd4VzKGG2IEG1NEBLN2OvJ{Kg[o9zKDFyIH3pcpM>	M2XIdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N\|g6Lz5{N{GzOlM5QTxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	ECAD / Vimentin / Sox2 / CD44 / CD133; PubMed: 30467925 Cancer Sci Yes-associated protein 1 (YAP1), E-cadherin, vimentin (epithelial-mesenchymal transition [EMT] pathway), SOX2 CD44 and CD133 (autophagy markers) were detected by western blot in control, verteporfin (1 μmol/L) and verteporfin + 231-taxol (0.5 μmol/L) resistance groups. c-Myc / Bcl-2; PubMed: 29416644 Oncotarget In CAL27 cell lines, the expression of BCL-2 and C-MYC proteins decreased with the increase of Verteporfin concentration. The presented columns are given as the means ± SD. p < 0.05, P < 0.01, **p < 0.001. p-S6(S240/244) / p-4EBP1(S65); PubMed: 28202507 Cancer Res KLE, EFE184 and NOU-1 were treated with Verteporfin (0.1 μM, 0.3 μM). After 36h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments. beta-catenin; PubMed: 28202507 Cancer Res KLE, EFE184, NOU-1 and SKUT-2 were treated with 3 μM Verteporfin. After 24h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.	30467925 29416644 28202507
Growth inhibition assay	Cell viability; PubMed: 28042502 Am J Cancer Res A: Cell viability was determined by MTS assay after the UM cells were exposed to verteporfin for 72 hours. B: After treated with various concentrations of verteporfin for 24 hours, the UM cells (e.g., 92.1, Mel 270, Omm 1, Omm 2.3) were seeded in drug-free soft agar culture for 14 days. Colonies were counted.	28042502
Immunofluorescence	p-YAP(Y357); PubMed: 28404908 Oncotarget Confocal images of HEC-1-B cells and organoids which were subjected to immunofluorescence detection of A. YAP and B. phospho-YAP after VP treatment. YAP and phospho-YAP are conjugated with goat anti-mouse and goat anti-rabbit Alexa flour secondary antibodies respectively. (A) Upper panel bar=63x and lower panel bar = 20x. (B) Upper panel bar=63x and lower panel bar = 20x. Calreticulin; PubMed: 30254296 Sci Rep Calreticulin (CRT) significantly increased in VP-treated (5 µM, 2 h) U87 cells in both 21% and 1% O2 indicating likely ER stress. YAP1; PubMed: 30254296 Sci Rep Treatment of U343 cells with 5 μM VP between 1-8 h in both 21% and 1% O2 induced morphological changes. Scale bar represents 10 µm. VP: Verteporfin	28404908 30254296

体内試験

Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. ^[1]

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

体外	DMSO	100 mg/mL (139.12 mM)
	Water	Insoluble
	Ethanol	Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Verteporfin (CL 318952) SDFをダウンロードする

分子量	718.79
化学式	C₄₁H₄₂N₄O₈
CAS No.	129497-78-5
Storage	3 years-20°C powder 2 years-80°C in solvent (in the dark)
別名	Visudyne
Smiles	COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C5N=C(C=C1[NH]2)C(=C5C)CCC(O)=O)C=C)C6=CC=C(C(C(=O)OC)C36C)C(=O)OC

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04590664	Recruiting	Drug: Verteporfin	Glioblastoma\|Recurrent Glioblastoma	Emory University\|National Cancer Institute (NCI)	January 15 2021	Phase 1\|Phase 2
NCT03797547	Active not recruiting	Other: AFLIBERCEPT	Myopic Choroidal Neovascularisation	Poitiers University Hospital	June 22 2018	--
NCT01846273	Completed	Drug: Ranibizumab\|Drug: Verteporfin PDT\|Drug: Sham PDT	Age-related Macular Degeneration\|Polypoidal Choroidal Vasculopathy	Novartis Pharmaceuticals\|Novartis	August 7 2013	Phase 4
NCT00423189	Terminated	Drug: Ranibizumab (Lucentis)\|Drug: 0.5mg ranibizumab	Age-Related Macular Degeneration	David M. Brown M.D.\|Novartis Pharmaceuticals\|Greater Houston Retina Research	January 2007	Phase 4
NCT00403442	Terminated	Device: Verteporfin Therapy/ Drug: Bevacizumab	Macular Degeneration	Vitreous -Retina- Macula Consultants of New York\|QLT Inc.	September 2006	Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

VDAシグナル伝達経路

相関VDA製品

PX-478 2HCl

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Defactinib (VS-6063)

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Plinabulin (NPI-2358)

Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.

Features:Synthetic analog of NPI-2350 and greater potentcy than NPI-2350.
Vadimezan (ASA404)

Vadimezan (ASA404, NSC 640488, DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
Dasatinib (BMS-354825)

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

研究分野別

製品類型

Verteporfin (CL 318952)

文献中Selleckの製品使用例(101)

製品安全説明書

VDA阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Verteporfin (CL 318952) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技術サポート

VDAシグナル伝達経路

相関VDA製品